

RECEIVED
MAY 27 2003
TECH. CENTER 1600/2900
Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31853C1	SERIAL NO. 09/939,4
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Buckingham, et al.	
		FILING DATE August 24, 2001	GROUP 1617

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>PC</i>	BC	4,895,862	1/23/90	Alessi, et al.	514	360	
<i>PC</i>	BD	5,068,342	11/26/91	Zask, et al.	548	183	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>PC</i>	BE	Iwamoto, et al., "Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM". <i>Diabetes Care</i> , <u>14(11)</u> : 1083-1086 (1991).
<i>PC</i>	BF	Hotta. <i>Tonyobyu</i> , <u>Update 10</u> : 68-77 (1994) (with translation).
<i>PC</i>	BG	Hotta. <i>Chronic Disease</i> , <u>6(1)</u> :1-9 (1995) (with translation).
<i>PC</i>	BH	Cusi, et al., "Metformin: A Review of its Metabolic Effects". <i>Diabetes Review</i> , <u>6(2)</u> : 89-131 (1998).
<i>PC</i>	BI	Arshag D. Mooradian. "Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly". <i>Drugs</i> , <u>51(6)</u> : 931-941 (1996).
<i>PC</i>	BJ	K. Doi. "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". <i>J. Japan Diabetes Science</i> , <u>3(Suppl. 1)</u> : 962-973 (1990) (with translation).
<i>PC</i>	BK	Kelley, et al., "Troglitazone". <i>Current Opinion in Endocrinology and Diabetes</i> , <u>5(2)</u> : 90-96 (1998).
<i>PC</i>	BL	A.J. Scheen. "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". <i>Drugs</i> , <u>54(3)</u> : 355-368 (1997).
<i>PC</i>	BM	Windholz, et al. <i>The Merck Index</i> , <u>10th Edition</u> : 635, Abstract Nos. 4300 & 4302 (1983).
<i>PC</i>	BN	H. Lebovitz. "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , <u>17(12)</u> : 1542-1544 (1994).
<i>PC</i>	BO	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPAR γ)". <i>The Journal of Biological Chemistry</i> , <u>270</u> : 12953-12956 (1995).
<i>PC</i>	BP	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and New Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , <u>37</u> : 311-320 (1994).
<i>PC</i>	BQ	Jackson, et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". <i>Diabetes</i> , <u>36</u> : 632-640 (1987).
<i>PC</i>	BR	Williams, et al., "Management of Non-Insulin-Dependent Diabetes Mellitus". <i>The Lancet</i> , <u>343</u> : 95-100 (1994).

EXAMINER <i>PC</i>	DATE CONSIDERED <i>9/8/03</i>
-----------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\k1s\cases\p31853c1\pto 1449 form.doc


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Buckingham, et al.FILING DATE
August 24, 2001GROUP
1617MAY 27 2003
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
TR	AH	6,153,632	11/28/00	Rieveley	514	369	
	AI	6,271,243	8/7/01	Ikeda, et al.	514	342	
	AJ	5,965,584	10/12/99	Ikeda, et al.	514	342	
	AK	6,150,383	11/21/00	Ikeda, et al.	514	342	
	AL	6,031,004	2/29/00	Timmins, et al.	514	635	
	AM	5,952,356	9/14/99	Ikeda, et al.	514	340	
	AN	6,291,495	9/18/01	Rieveley	514	369	
	AO	5,900,435	5/4/99	Martin D. Meglasson	514	565	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AP	WO 97/17975	5/22/97	PCT				
	AQ	WO 98/36755	8/1998	PCT				
	AR	0 861 666 A2	9/1998	EPO				
	AS	WO 95/21608	8/1995	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT	Weinstock, et al., "Pioglitazone: In Vitro Effects on Rap Hepatoma Cells and In Vivo Liver Hypertrophy in KKA ^y Mice". <i>Pharmacology</i> , 54: 169-178 (1997).
AU	Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers". <i>Diabetes Care</i> , 15(8): 1075-1078 (1992).
AV	Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in Non-Insulin Dependent Diabetics". <i>Diabetologia</i> , 38(S1): A44 (1995).
AW	Whitcomb, et al., "Thiazolidinediones". <i>Exp. Opin. Invest. Drugs</i> , 4(12): 1299-1309 (1995).
AX	Inzucchi, et al., "Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus". <i>New England Journal of Medicine</i> , 338(13): 867-872 (1998).
AY	Ishida, et al., "Oral Hypoglycemic Agents - New Oral Drugs and New Strategy of Treatment". <i>Clinic All-Round</i> , 43: 2615-2621 (1994).
AZ	Hermann, et al., "Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations". <i>Diabetes Care</i> , 17(10): 1100-1109 (1994).
BA	Haupt, et al., "Oral Antidiabetic Combination Therapy with Sulphonylureas and Metformin". <i>Diabete & Metabolisme</i> , 17: 224-231 (1991).
BB	Scheen, et al., "Oral Antidiabetic Agents". <i>Drugs</i> , 55(2): 225-236 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.